4.25 +0.05 (1.19%)
After hours: 5:40PM EST
|Bid||4.15 x 200|
|Ask||4.25 x 1000|
|Day's range||4.15 - 4.30|
|52-week range||3.78 - 13.05|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.50|
On a per-share basis, the Seattle-based company said it had a loss of 52 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.